Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

Homepage
Tags search
Compugen

CTech 24/7

15:32 "We’ve never seen such destruction before": Israel faces over $1.3 billion in property damage from Iran war
14:57 Tehran trembles: Israel-Iran war redraws Middle East power map
14:44 Rafael expands R&D footprint with $153M real estate deal in Tel Aviv
14:29 With manpower tight, Israeli tech leans on offshore and hybrid workforces

Compugen

5 stories about Compugen

Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23|Sophie ShulmanThe Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19|Lilach BaumerThe Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18|Dror ReichThe investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18|Dror ReichThe Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18|Lilach BaumerThe deal has the potential to be worth over $200 million for Nasdaq-listed Compugen

Twitter

Facebook

Rss

About CTech Terms of Use Privacy Policy

CTech 24/7

Compugen

Compugen shares soar on massive deal with Gilead, worth up to $848 million

Compugen Falls 17% on Employee Cuts Announcement

Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen

Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering

AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen